MultiCell Technologies has appointed Stephen M. Chang, Ph.D. as its new CEO in addition to his current role as president.
PAREXEL International has named Douglas A. Batt senior vice president and general counsel.
MGI PHARMA announced that Gerard T. Kennealey, M.D. has joined the management team in the newly-created position of senior vice president, clinical development.
Zila has appointed Frank J. Bellizzi president of its wholly owned subsidiary, Zila Pharmaceuticals, as well as executive vice president of business development for Zila.
Corgentech has named Susan Kramer, Dr.P.H. vice president of preclinical development.
Valera Pharmaceuticals has appointed Jeremy D. Middleton to the newly created position of vice president, business development.
Stiefel Laboratories has named Jim Loerop vice president of corporate development.
Abraxis BioScience named its executive committee and seven officers to its executive management team: Richard E. Maroun as chief administrative officer; Thomas H. Silberg as executive vice president, commercial operations & operational excellence; John F. Weidenbruch as general counsel and assistant corporate secretary; Bruce Wendel as executive vice president, corporate development; and Ronald E. Pauli as interim chief financial officer. Frank Harmon has joined the company as executive vice president, global operations. Nicole S. Williams, who has served as CFO and president of the Abraxis Pharmaceutical Products division, will retire from APP to pursue other opportunities. Carlo Montagner continues as president of Abraxis Oncology. These seven executives will form the executive committee of Abraxis BioScience.
Neurobiological Technologies has appointed David C. Chou, Ph.D., to the position of director of chemistry, manufacturing and controls.
Carrington Laboratories has promoted Yawei Ni, Ph.D., to senior scientist at DelSite Biotechnologies.
ProMetic Life Sciences announced that General Counsel Genevieve Lavertu is leaving the company to pursue her legal practice in Toronto and is being replaced by Mark Bandrauk.
CytoDyn has appointed Jonathan R. Leong to its board of directors to fill a vacancy.
Onconova Therapeutics has elected Michael Hoffman chairman of the company's board of directors.
Invitrogen Corp. has formed a Flow Cytometry Scientific Advisory Board to be chaired by Dr. Leonard A. Herzenberg.
Miraculins has re-elected Dr. Albert Friesen, Dr. Phiet Bui, Mr. David Filmon, Mr. Peter de Visser and Mr. Ted Paetkau to the company's board of directors.
CombiMatrix Molecular Diagnostics has named genomics expert Stephen W. Scherer, Ph.D. to its scientific advisory board.
Archemix announced today that John Maraganore, Ph.D. has been appointed to the company's board of directors.
Advanced Viral Research has appointed Angelo S. Botter to the board of directors.